Speaker Profile
Ph.D., Chief Executive Officer, BioEclipse Therapeutics, Inc.
Biography
Life science executive, scientist, and entrepreneur. Dr. Contag is an experienced senior executive for both public (President and CEO, Xenogen Corp., NASDAQ: XGEN), and multiple private companies including, most recently Origen Therapeutics, Cygnet Biofuels, and Cobalt Technologies. Dr. Contag has extensive experience leading science and business teams for pioneering biomedical technology companies. While serving as CEO of Xenogen, in 2000, Xenogen was listed as one of the “Top 25 Young Businesses” by Fortune Small Business and in both 2001 and 2003 the company received the R&D 100 award for achievements in Physics. In 2004, Xenogen was named as one of the top 100 fastest growing companies by the San Francisco Times, received the Frost and Sullivan Technology Innovations award, and the company completed a successful initial public offering (NASDAQ: XGEN). Dr. Contag was named one of the “Top 25 Women in Small Business” by Fortune magazine. She was also awarded the Northstar Award from Springboard Enterprises. While serving as CEO & Chairman of Cobalt Technologies, the company was named one of the top 20 cleantech companies. In 2011, Dr. Contag was awarded “Cleantech Innovator of the Year” award for technology developed at Cygnet Biofuels. With more than 25 years of microbiology research experience, Dr. Contag is widely published in the field of Microbiology and Optical imaging, and has over 35 patents in Biotechnology. Dr. Contag received her Ph.D. in Microbiology at the University of Minnesota Medical School in 1989 studying Microbial Physiology and Genetics (for Alternative Fuels), and completed her Postdoctoral Training at Stanford University School of Medicine in 1993 specializing in “Host/Pathogen Interactions”.
Presentation Title and Company Description
Immunotherapy Showcase: Targeted Dual Biotherapy For Resistant & Recurring Cancer
In contrast to competing cancer immunotherapies (CarT, Checkpoint Inhibitors) that typically only attack via one mechanism, BioEclipse’s dual biotherapy is multi-mechanistic, targeting both early and late mechanisms, thereby reducing the potential for relapse, especially in later stage disease.
